Jump to content
Powered by

Hölle & Hüttner - takeover of the share capital of INTAVIS AG

Tübingen-based Hölle & Hüttner AG is taking over the entire share capital of Cologne-based INTAVIS Bioanalytical Instruments AG retroactively as of 1 January 2008. Both companies specialise in the development and marketing of systems for the automation of biochemical and molecular biological processes.

The acquisition makes Hölle & Hüttner the sole commercial provider worldwide of automated systems for in situ hybridisation and immunohistochemistry within the field of research. These systems are special processes for the detection of specific DNA or RNA sequences or proteins in individual cells, tissues or entire organisms.

Since the decoding of the human genome, scientists have been able to identify around 1.500 “disorder genes“. However, more than one gene is almost always involved in the development of hereditary diseases and the interactions of these genes are often not yet understood in detail. The in situ hybridisation technology makes it possible to determine the presence of disorder genes under the microscope with comparatively little effort. This method can be used when it is necessary to detect and show certain genes or DNA or RNA sequences in situ, i.e. in natural structures, for example in prenatal diagnostics and for the detection of certain viruses in a human organism or salmonella bacteria in food.

Dr. Steffen Hüttner (right) and Peter Beck, Managing Directors of Hölle & Hüttner (Photo:Hölle & Hüttner AG)
Dr. Steffen Hüttner (right) and Peter Beck, Managing Directors of Hölle & Hüttner (Photo: Hölle & Hüttner AG)

Acquisition increases future potential

Developmental biology also employs in situ hybridisation to demonstrate the distribution patterns of gene activities in model organisms. Differently marked gene probes – short DNA or RNA sequences – are used herein to “hybridise”, i.e. bind to their respective matching DNA or RNA counterpart in situ. Specific antibodies which bind to proteins and reveal their localisation in cells or tissues are used for immunohistochemical purposes.
Since 2004, Hölle & Hüttner AG from the STERN BioRegion has firmly established itself with its BioLane instruments for routine applications with an automated system for in situ hybridisation and, up to now, has been one of the two providers worldwide in this business sector. In order to further expand this enormous potential, Dr. Steffen Hüttner and Peter Beck, Managing Directors of Hölle & Hüttner, initiated a meeting with their competitor INTAVIS Bioanalytical Instruments AG, which has a higher turnover. The future course – the takeover of the share capital of INTAVIS AG through Hölle & Hüttner AG – was already established during the first meeting. Legally, both Hölle & Hüttner and INTAVIS will remain two independent companies. By signing the contract, Peter Beck will become the managing director of INTAVIS AG and Dr. Steffen Hüttner will take over as chairman of the supervisory board. The previous sole share holder and managing director of INTAVIS AG, Dr. Heinrich Gausepohl, will continue to work for the company as a senior executive.
For the time being, however, Peter Beck does not see any need for drastic changes at INTAVIS. “We are not pressed for time. The company is well-structured and running successfully“. After the integration period, innovations may be considered. “Due to the fact that we no longer need to compete with a rival but are now cooperating, an enormous future potential is arising in the sector of in situ hybridisation“, says Dr. Steffen Hüttner.

Source: BioRegio STERN Management GmbH - 19.07.08
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/hoelle-huettner-takeover-of-the-share-capital-of-intavis-ag